

Gunderson Dettmer Represented TCG Crossover (“TCG X”) for its Inaugural \$824 Million Fund

Client News

July 23, 2021

Gunderson Dettmer represented TCG Crossover in its inaugural \$824 million fund. TCG Crossover invests in innovative drug discovery companies that are seeking to make an impact on unmet medical needs. In connection with its relationship with The Column Group, TCG Crossover adds extensive scientific and operating expertise to its portfolio companies.

The Gunderson team consisted of Andrew Thornborrow, Tony Huynh, Jason Li and David Eberle

Related People



Andrew M. Thornborrow

PARTNER

P +1 650 463 5298

Related Services

Private Fund

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act